

- This comprehensive and up-to-date network meta-analysis (NMA) analyzed both direct and indirect evidence to compare the efficacy outcomes of telbivudine versus adefovir, entecavir, lamivudine, and tenofovir in nucleos(t)ide-naïve hepatitis B e antigen-positive patients with chronic hepatitis B.
- A systematic review was conducted to search databases for publications of randomized controlled trials (RCTs).
- In total, 75 RCTs were included in the NMA.
- At 1 year, telbivudine was superior to adefovir, entecavir and lamivudine in hepatitis B e antigen (HBeAg) seroconversion, and to entecavir and lamivudine in HBeAg loss.
- Telbivudine was also superior to lamivudine in alanine aminotransferase normalization and to adefovir and lamivudine in suppressing hepatitis B virus DNA levels.

This summary slide represents the opinions of the authors. Article processing charges and the open access charge for this NMA were funded by Novartis Pharma AG. The authors thank Rajeeb Ghosh, Novartis Healthcare Pvt. Ltd., for medical writing support. Funding for writing support was provided by Novartis Pharma AG. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online.

© The Author(s) 2016. Creative Commons Attribution Noncommercial License (CC BY-NC).